24th Annual Biotech in Europe Forum by Sachs Associates

Back for its 24th Annual Edition, this global bio-pharma industry event will address the main challenges in investment for 2024 as well as partnering and alliance management and prospects for 2025. Key players will contribute their insights in panels, which will cover the macro picture as well as innovation in different therapeutic sectors. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners.

The main programme for the 24th Annual BEF is spread throughout 2 days and will feature more than 15 hours of high-level keynotes and panel discussions. In addition, there will be a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities. This will include a limited number of live presentations taking place in dedicated parallel presentation tracks, alongside virtual company showcases, which will be available on-demand during the virtual week. We anticipate 600+ delegates will register for the forum from all sectors of Life Sciences, with the target audience being corporate and financial investors/partners, banks and advisors, with part of the audience participating virtually.

Members of the Swiss Biotech Association benefit from a 15% discount on registration or showcase packages with Online Meeting System Access.